Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aronex Pharma (ARNX) -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (295)	9/25/1999 9:12:00 AM
From: kendall harmon	Respond to of 320

ARNX--more on the Conference at which they are presenting Sunday: <<A great way for biotech investors to make potentially quick gains is to watch the scientific conference schedule and figure out which companies will be spotlighted. This is a great forum for biotechs to strut their stuff in front of analysts and institutions that may not have previously known anything about the company. The bigger the conference is, the better the national exposure. Stocks sometimes move higher with positive data on products, and occasionally tank on better news from a competitor, even if the company presents positive results itself. The Interscience Conference on Antimicrobial Agents and Chemotherapy is a conference that focuses on infectious diseases, and is scheduled Sept. 26-29 in San Francisco. ICAAC has become one of the major scientific forums for presentations on pipeline products for HIV and AIDS. This year's conference will include data from products that treat diseases such as influenza (the flu) and the common cold. The best forum to display positive results is the "late-breaking" sessions. The conference room during these sessions is packed liked a can of sardines, with mutual fund managers and physicians standing side by side awaiting a company's announcement that it has a cure for AIDS. It's been said that more than five times as many studies are submitted as are eventually accepted. How do you find out about the late-breaker sessions? Call companies directly, fastidiously check out the conference Web site and read analyst reports - there are numerous ways. >> Source: ragingbull.com <<Anthony H. Williams, M.D., Vice President Medical Affairs, Aronex Pharmaceuticals, will present data from the completed Phase III clinical trial, which evaluated NYOTRAN in 538 patients with presumed fungal infections who had failed 72 hours of previous antibacterial therapy. The data will be presented on Sunday, September 26, 1999, at 12:24 p.m. in Late Breaker Session Number 29 in Room 103/104. Five separate posters or presentations on NYOTRAN will be presented during the ICAAC conference from September 26-29, 1999. A schedule of the presentations and posters is listed below, and copies of the abstracts may be obtained from the ICAAC website at www.asmusa.org, or by contacting Aronex Pharmaceuticals' Corporate Communications Department.>>

To: aknahow who wrote (295)	9/26/1999 5:46:00 PM
From: kendall harmon	Respond to of 320

ARNX--positive news from California << Aronex's Nyotran Anti-Fungal Drug Safe, Potent, Key Study Says San Francisco, California, Sept. 26 (Bloomberg) -- Aronex Pharmaceuticals Inc.'s experimental anti-fungal drug appeared to fight tough infections as well as a commonly used generic drug, and may pose less risk of kidney problems, new research suggests. Data from a 538-patient study indicate that the drug, Nyotran, works to fight dangerous fungal infections that mainly strike people who have had their immune systems damaged by cancer treatment or disease. The two drugs had similar efficacy against fungal infection, but patients on Nyotran had significantly fewer kidney problems than patients taking a standard anti-fungal drug called Amphotericin B. ''In this study, Nyotran was as effective in therapeutic terms,'' said Anthony Williams, the Aronex official who presented the data. ''Despite slightly higher infusion-related problems, it caused considerably less (kidney) toxicity.'' The data was presented during a special session on the opening day of the Interscience Conference on Antimicrobial Agents and Chemotherapy, being held this week in San Francisco. The so-called ''late-breaker'' session highlights a handful of studies that conference organizers deemed particularly important. The data could give a boost to the money-losing company, which announced after markets closed on Friday that the U.S. Food and Drug Administration rejected its bid to sell a leukemia drug that would have become its first drug on U.S. markets. Aronex shares rose 1/8 to 4 5/8 Friday, down about 35 percent since Aronex disclosed potential FDA problems for the leukemia treatment, called Atragen. Nyotran is a reformulated version of a commonly used generic drug called nystatin. Scientists at Aronex wrapped nystatin, a topical treatment, in a fatty capsule called a liposome which buffers side effects and allows Nyotran to be given intravenously. Aronex has said it plans to file an application for government approval of Nyotran this year. Aronex has a licensing agreement for Nyotran with Abbott Laboratories valued at as much as $40 million. If approved, the drug would also compete against new liposomal anti-fungals such as Gilead Sciences Inc.'s Ambisome, and Liposome Co.'s Abelcet. These more expensive drugs are designed to be easier to tolerate and have fewer risky side effects than Amphotericin B, which was introduced in the 1960s and has been the standard drug for fighting fungal infections. Both Bristol-Myers Squibb Co. and Pharmacia & Upjohn Inc. sell versions of Amphotericin B. Based in the Houston suburb of The Woodlands, Aronex was formed in a 1995 three-way merger of Argus Pharmaceuticals Inc., Triplex Pharmaceutical Corp., and Oncologix Inc.>> quote.bloomberg.com